Planning Intermittent CalciNeurin Inhibitor Controls—The piCNIc Retrospective Cohort Study
Veronica Bellissimo, Lilia Tran, Gaëlle Bernard‐Tessier, Jean‐Simon Denault, Sarah Pelletier, Andreea‐Adelina Statie, Nathalie Letarte, Geneviève Huard, Julie Morisset, Victor Ferreira · 2026
Read Planning Intermittent CalciNeurin Inhibitor Controls—The piCNIc Retrospective Cohort Study by Veronica Bellissimo, Lilia Tran, Gaëlle Bernard‐Tessier, Jean‐Simon Denault, Sarah Pelletier, Andreea‐Adelina Statie, Nathalie Letarte, Geneviève Huard, Julie Morisset, Victor Ferreira (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421019.txt.
Description
Veronica Bellissimo and co-authors evaluate a pharmacist-led protocol that reduced how often transplant patients' drug levels are checked. Calcineurin inhibitors, key anti-rejection drugs after organ transplantation, need blood monitoring because safe levels sit in a narrow range. Their 2026 retrospective study, called piCNIc, was run at a Montreal university hospital.
The team compared 254 hospitalisations before the protocol with 266 after it, covering liver, kidney, and lung transplant patients in 2023 and 2024. Monitoring fell by about one measurement per patient per week, a decrease of 14.0 percent, after adjustment. Rates of hitting target drug levels and of dose adjustments did not differ between periods, and drug-related side effects were similar. The authors conclude that less frequent, standardised monitoring saved resources without harming target achievement or safety.
Catalog record
| CREATOR | Veronica Bellissimo, Lilia Tran, Gaëlle Bernard‐Tessier, Jean‐Simon Denault, Sarah Pelletier, Andreea‐Adelina Statie, Nathalie Letarte, Geneviève Huard, Julie Morisset, Victor Ferreira |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |